System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Studies

Observational Active not recruiting

NCT03460769 on ClinicalTrials.gov

Evaluation of a Mixed Meal Test for Diagnosis and Characterization and Type 3c Diabetes Mellitus Secondary to Pancreatic Cancer and Chronic Pancreatitis (DETECT)

  • Sponsor: The University of Texas MD Anderson Cancer Center
  • Collaborators: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
  • Enrollment: 775 (Estimated)
  • Study start: 2021-04-01 (Actual)
  • Primary completion: 2027-06-30 (Estimated)
  • Study completion: 2027-06-30 (Estimated)
  • Allocation: N/a
  • InterventionModel: N/a
  • Masking: None
  • PrimaryPurpose: Other

Brief Summary

The Coordinating and Data Management Center (CDMC) at MD Anderson Cancer will be responsible for the coordination and data management for the Evaluation of a mixed meal test for Diagnosis and characterization of Type 3c diabetes mellitus secondary to pancreatic cancer and chronic pancreatitis (DETECT), which is part of the NIH U01 funded Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer (CPDPC). Similar to all studies that will be coordinated and managed by the CDMC, no patient enrollment will occur at MDACC. All patient recruitment will occur at external sites that are a part of the CPDPC, which are listed in the appended DETECT protocol. The data management systems, auditing, and monitoring effort are supported by the CDMC.

Conditions

  • Pancreatic Cancer
  • Chronic Pancreatitis
  • Diabetes Mellitus Type 3c

Intervention / Treatment

  • Other: Data Management and Monitoring

Primary Outcome Measures

  • Protocol and Regulatory Compliance Monitoring of Regulatory Documents for Consortium Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer (CPDPC) (3 years)
    The Coordinating and Data Management Center (CDMC) at MD Anderson Cancer Center will monitor protocol and regulatory compliance at all participating institutions.

Countries

United States

Locations and Investigators

  • Cedars-Sinai Medical Center, Los Angeles, United States
  • Stanford University, Stanford, United States
  • University of Florida, Gainesville, United States
  • Indiana University, Carmel, United States
  • University of Minnesota, Minneapolis, United States
  • Mayo Clinic, Rochester, United States
  • Ohio State University, Columbus, United States
  • University of Pittsburgh Medical Center, Pittsburgh, United States
  • Baylor College of Medicine, Houston, United States
  • University of Texas MD Anderson Cancer Center, Houston, United States

Study Officials